Results for “framework”

Build the ATM framework runner and sync it to explicit internal adopter repositories with skip/exclude controls.

The English summary is being prepared. Showing the original description.

Plan ATM framework refactors by preserving atom/map semantics before splitting large governance modules.

The English summary is being prepared. Showing the original description.

ATM Captain 派工治理。觸發詞 派工 / 派工單 / dispatch / 開卡 / 派任務 / 派代理 / Phase 0 / Phase 1 / AAO / task card / condition review / 收口。負責 AI-Atomic-Framework (AAF) + 3KLife 雙 repo 治理：強制 Context Map 4 層、雙代理拆分（防外卡 mirror commit）、AAF 嚴格 2 commit、3KLife target_repo 嚴格 1 commit、7-8 段回報、禁止清單前置強化、Captain condition review。承載 0064 → 0093+ 累積的紀律教訓。

The English summary is being prepared. Showing the original description.

ATM 版本升級與開源 release train 工作流。USE FOR: ATM frameworkVersion 升級、release impact 分類、SemVer 決策、CODEOWNERS / changeset / release gate 檢查、ATM upstream release docs 維護。

The English summary is being prepared. Showing the original description.

Idiomatic Go - package and interface design, error wrapping, table-driven tests, generics, the modern standard library (slices/maps/cmp/errors.Join), current syntax, and logging discipline. Use when writing, reviewing, or refactoring any Go code, especially code drifting toward Java/Spring shapes (deep layer trees, generic repositories, heavy frameworks) - even if the user never says "idiomatic". Distilled from spf13/go-skills and adapted to this repo.

The English summary is being prepared. Showing the original description.

Capture the "why" behind technical choices to prevent architectural drift. Load when the user makes a major technical decision, chooses a library/framework, defines a system boundary, or changes a core architectural pattern. Also triggers on "record a decision", "write an ADR", "why did we do this", "document this architectural choice", or "architectural decision record". Supports `SYNTHESIS=true` mode for retrospective ADR backfill from observed repo state — used by `retroactive-project-setup` and any future backfill skill. Essential for long-term project maintainability and agent alignment.

The English summary is being prepared. Showing the original description.

Prisma Compute deployment and hosting guide. Use whenever the user mentions Prisma Compute, `prisma.compute.ts`, `defineComputeConfig`, deploying or hosting a Prisma app, `@prisma/cli app deploy`, `compute:deploy`, `create-prisma --deploy`, `PRISMA_SERVICE_TOKEN`, Compute auth/workspaces, apps/deployments/build logs/domains, localhost vs `0.0.0.0`, deploy port binding, or framework deploy readiness for Hono, Elysia, Next.js, TanStack Start, Astro, Nuxt, Svelte, Nest, Turborepo, or custom/prebuilt artifacts.

The English summary is being prepared. Showing the original description.

Use this skill when the user requests to generate, create, or write professional research reports including but not limited to market analysis, consumer insights, brand analysis, financial analysis, industry research, competitive intelligence, investment due diligence, or any consulting-grade analytical report. This skill operates in two phases — (1) generating a structured analysis framework with chapter skeleton, data query requirements, and analysis logic, and (2) after data collection by other skills, producing the final consulting-grade report with structured narratives, embedded charts, and strategic insights.

The English summary is being prepared. Showing the original description.

Master modern business analysis with AI-powered analytics, real-time dashboards, and data-driven insights. Build comprehensive KPI frameworks, predictive models, and strategic recommendations.

The English summary is being prepared. Showing the original description.

Build robust, production-grade backtesting systems that avoid common pitfalls and produce reliable strategy performance estimates.

The English summary is being prepared. Showing the original description.

Architectural decision-making framework. Requirements analysis, trade-off evaluation, ADR documentation. Use when making architecture decisions or analyzing system design.

The English summary is being prepared. Showing the original description.

Build content-focused websites with Astro — zero JS by default, islands architecture, multi-framework components, and Markdown/MDX support.

The English summary is being prepared. Showing the original description.

Delimits putative species boundaries from molecular data within the de Queiroz 2007 unified-lineage framework using ASAP (Puillandre 2021 successor to ABGD), mPTP C++ (Kapli 2017 successor to bPTP; bPTP is Python NOT R), GMYC single/multi-threshold (Pons 2006; Fujisawa 2013), multilocus BPP v4 with prior calibration from data (NOT defaults; Yang 2015), SNAPP + BFD* for SNP delimitation, DELINEATE (Sukumaran 2021) speciation-process modeling to address Sukumaran & Knowles 2017 PNAS critique that MSC delimits structure not species, integrative-taxonomy congruence (Padial 2010; Carstens 2013), Dsuite for introgression testing before sister claims (Malinsky 2021), and Meyer & Paulay 2005 barcoding-gap-absence caveat. Use when delineating species from DNA barcoding data, resolving cryptic complexes, choosing among ASAP/mPTP/BPP/DELINEATE, calibrating BPP priors, distinguishing introgression from ILS, or applying the Sukumaran-Knowles oversplitting correction.

The English summary is being prepared. Showing the original description.

Performs differential expression on bulk RNA-seq count data with edgeR's negative-binomial GLM and quasi-likelihood F-test framework. Covers DGEList construction, filterByExpr, TMM/TMMwsp normalization, robust dispersion estimation, glmQLFit/glmQLFTest, TREAT for magnitude-bounded hypotheses, contrasts via no-intercept designs, voom and voomWithQualityWeights for heterogeneous samples, and the edgeR v4 bias-corrected APL changes. Use when running bulk DE with edgeR, choosing edgeR over DESeq2 (small n, transcript DE via catchSalmon, large samples), needing TREAT for a fold-change-threshold hypothesis, troubleshooting v3-to-v4 reproducibility, building paired or interaction designs, or handling library-quality heterogeneity.

The English summary is being prepared. Showing the original description.

Analyzes single-cell pooled CRISPR screens (Perturb-seq, CROP-seq, Perturb-CITE-seq, ECCITE-seq, multiome) where each cell carries an sgRNA and a scRNA-seq / surface-protein / chromatin readout. Covers experimental design (direct-capture Perturb-seq Dixit 2016 vs CROP-seq 3'UTR-barcoded Datlinger 2017 vs ECCITE-seq vs Multiome), MOI for sgRNA assignment, escaper-cell filtering (Mixscape, Papalexi 2021), SCEPTRE NB GLM + permutation for low-MOI (Barry 2024 Genome Biol 25:124), the Pertpy framework, factor decomposition, genome-scale Perturb-seq (Replogle 2022 Cell, 2.5M cells), and per-perturbation single-cell DE. Use when running a single-cell CRISPR screen, choosing direct-capture vs CROP-seq architecture, filtering escaper cells, performing single-cell DE, integrating Perturb-seq with pathway analysis, scaling to GW CRISPRi via Replogle protocol, or analyzing multi-omics screens.

The English summary is being prepared. Showing the original description.

Detect introgression and admixture between species or populations using Dsuite (Malinsky 2021 fast D-statistics), Patterson's D / ABBA-BABA test (Green 2010; Durand 2011), f4-ratio and f-branch statistic (Malinsky 2018), TreeMix (Pickrell & Pritchard 2012), HyDe (Blischak 2018), QuIBL (Edelman 2019), sprime (Browning 2018), Twisst (Martin 2017), PhyloNet (Solis-Lemus 2017) for explicit phylogenetic networks, and qpAdm / qpGraph (Patterson 2012; Lipson 2013). Distinguish introgression from incomplete lineage sorting (ILS), ancestral structure, ghost-lineage admixture, and rate variation. Use when testing inter-species gene flow, dating admixture events, identifying introgressed segments, building phylogenetic networks for reticulate evolution, or applying the ABBAclustering (Koppetsch-Malinsky-Matschiner 2024) framework for divergent-species gene flow.

The English summary is being prepared. Showing the original description.

Queries gnomAD v4 (807k samples), v3, v2.1.1, and constraint metrics with grpmax FAF95, bottleneck-group exclusion, LOEUF interpretation, SV/CNV/mtDNA catalogs, and Whiffin max-credible-AF framework. Use when filtering rare variants, applying ACMG BS1/BA1, ranking genes by LoF intolerance, or selecting between v2 (GRCh37 + chrX/Y constraint) and v4 (GRCh38 + 807k samples).

The English summary is being prepared. Showing the original description.

Classify constitutional (germline) copy number variants for clinical reporting using the 2019 ACMG/ClinGen technical standards points-based framework, with ClassifyCNV and AnnotSV for semi-automated scoring. Covers the separate copy-number-loss and copy-number-gain rubrics, the five-tier classification, ClinGen haploinsufficiency/triplosensitivity and dosage-sensitive regions, de novo and segregation evidence, and population-frequency benign evidence. Use when assigning pathogenic/likely-pathogenic/VUS/likely-benign/benign to a constitutional CNV, scoring a CNV against ACMG/ClinGen criteria, or distinguishing the automatable evidence from the case-specific evidence requiring manual input.

The English summary is being prepared. Showing the original description.

Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 7.

The English summary is being prepared. Showing the original description.

Performs subgroup and heterogeneous treatment effect (HTE) analyses for clinical trials. Covers Mantel-Haenszel pooling, Breslow-Day, interaction tests in regression, RERI for additive interaction, modern data-adaptive HTE methods (STEPP, SIDES, causal forests, X/R-learners), Bayesian shrinkage (Dixon-Simon, MAP, EXNEX), graphical multiplicity (Bretz-Maurer), and credibility frameworks (Sun BMJ, EMA 2019). Use when analyzing treatment effects across patient subgroups for regulatory submissions or precision-medicine claims.

The English summary is being prepared. Showing the original description.

Queries ClinVar for variant pathogenicity classifications, ClinGen VCEP curations, and somatic-vs-germline interpretations via REST API, weekly VCF, or bulk XML. Use when determining clinical significance, triangulating conflicting interpretations, or aggregating evidence against the ACMG/AMP framework with ClinGen SVI specifications.

The English summary is being prepared. Showing the original description.

Prioritizes rare-disease variants from trio/quad WES/WGS with de novo (DeNovoGear, Triodenovo), compound-heterozygous phasing (WhatsHap), mosaic VAF tiering, phenotype-driven ranking (Exomiser, Phen2Gene, AMELIE), ClinGen gene-disease validity gating, and ACMG SF v3.2 secondary findings reporting. Use when running diagnostic exome / genome pipelines, identifying candidate Mendelian disease genes, screening for incidental findings, or auditing VUS reclassification cycles. The ACMG/AMP classification framework (PVS1 decision tree, Pejaver PP3/BP4 calibration, Tavtigian point system) is in clinical-databases/acmg-classification.

The English summary is being prepared. Showing the original description.

Analyzes chemical libraries by scaffold using Bemis-Murcko scaffolds, generic frameworks, cyclic skeletons, matched molecular pair (MMP) analysis via mmpdb, R-group decomposition, Free-Wilson analysis, scaffold hopping, and chemotype-aware ML train/test splits. Use when identifying chemotype clusters in a library, deriving SAR transformation rules, decomposing series into R-groups, performing scaffold-balanced QSAR splits, or planning analog campaigns.

The English summary is being prepared. Showing the original description.

Runs cis-pQTL Mendelian randomization for drug-target validation using UKB-PPP (Olink), deCODE (SomaScan), Fenland, INTERVAL, ARIC, and FinnGen-PPP proteomes plus colocalization triangulation, phenome-wide on-target adverse-effect scans, cross-platform Olink/SomaScan replication, and PAV (protein-altering variant) sensitivity. Use when nominating or de-risking a drug target from plasma-proteome GWAS, mimicking pharmacological inhibition via cis-pQTL instruments, separating shared-causal from LD-confounded signal under the Schmidt 2020 cis-MR framework, screening on-target adverse phenotypes pheWAS-style, or producing publication-grade STROBE-MR plus PP.H4 evidence for a target gene.

The English summary is being prepared. Showing the original description.